Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561883 | 0.79 | KCNH2 (0.61) | KCNH2SMN1; SMN2LMNAMAPTOPRM1 | |
| SCHEMBL14497613 | 0.79 | KCNH2 (0.61) | KCNH2SMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL14497609 | 0.79 | KCNH2 (0.61) | KCNH2SMN1; SMN2LMNAMAPTOPRM1 | |
| SCHEMBL14497614 | 0.79 | KCNH2 (0.61) | KCNH2SMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL14497610 | 0.79 | KCNH2 (0.61) | KCNH2SMN1; SMN2LMNAMAPTOPRM1 | |
| SCHEMBL24900873 | 0.76 | KCNH2 (1.00) | KCNH2SMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL24900856 | 0.76 | KCNH2 (1.00) | KCNH2SMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL24900941 | 0.76 | KCNH2 (1.00) | KCNH2SMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL2120097 | 0.76 | KCNH2 (1.00) | KCNH2SMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL24900949 | 0.76 | KCNH2 (1.00) | KCNH2SMN1; SMN2LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458439-B1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO INC (US) | 2021-12-08 | — | — | EP | disclosed |
| US-11192857-B2 | 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use | ALERE SAN DIEGO, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190292148-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3458439-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | Alere San Diego, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201314-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | ALERE SAN DIEGO, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192857-B2 | 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use | DPYSL2, DNPEP, DPYSL3 | KCNH2 4297/4885SMN1; SMN2 2130/4885LMNA 2553/4885 |
| US-20190292148-A1 | 2-ETHYLIDENE-1,5-DIMETHYL-3,3-DIPHENYLPYRROLIDINE ANALOGS AND METHODS FOR THEIR SYNTHESIS AND USE | DPYSL2, DNPEP, DPYSL3 | KCNH2 4297/4885SMN1; SMN2 2130/4885LMNA 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.